Prognostic Role of Modified Glasgow Prognostic Score in metastatic Renal Cell Carcinoma Patients Treated with Nivolumab: Single-Center Experience
Abstract
Aim: This study aimed to evaluate the prognostic significance of the modified Glasgow Prognostic Score (mGPS) in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab monotherapy.
Methods: We retrospectively analyzed 80 patients with mRCC who received at least one cycle of nivolumab between February 2016 and March 2024 at a single academic center. Patients were categorized into three groups according to pre-treatment mGPS (0, 1, or 2). Survival outcomes were assessed using the Kaplan–Meier method.
Results: The median progression-free survival (mPFS) was 31.3, 6.8, and 4.4 months in patients with mGPS 0, 1, and 2, respectively (p = 0.001). The median overall survival (mOS) was 33.4 months for mGPS 0, 14.1 months for mGPS 1, and 6.7 months for mGPS 2 (p = 0.001). mGPS was significantly associated with both PFS and OS. Notably, patients with mGPS 0 had substantially better survival outcomes. These findings suggest a potential association between higher systemic inflammation (as reflected by mGPS) and adverse prognostic features. mGPS demonstrated partial overlap with the IMDC (International Metastatic RCC Database Consortium) classification but offered additional prognostic stratification due to its incorporation of inflammatory markers.
Conclusion: mGPS is a simple, objective, and clinically applicable biomarker that may support survival prediction and patient selection in the context of ICI therapy for mRCC. Its integration into routine clinical decision-making could enhance personalized treatment strategies. Prospective studies in larger cohorts are needed to validate these findings.
Keywords
Metastatic renal cell carcinoma, Nivolumab, Modifiye Glasgow Prognostic Score
Supporting Institution
no
Ethical Statement
This study was conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval was obtained from the Necmettin Erbakan University Ethics Committee (Application ID: 2518; Decision No: 2025/5839). Written informed consent was obtained from all participants.
Thanks
SAYGILARIMLA.
References
- 1. Ishihara, Hiroki, et al. "Predictive impact of peripheral blood markers and C-reactive protein in nivolumab therapy for metastatic renal cell carcinoma." Targeted Oncology 14.4 (2019): 453-463.
- 2. Yano, Yusuke, et al. "Serum C-reactive protein level predicts overall survival for clear cell and non-clear cell renal cell carcinoma treated with ipilimumab plus nivolumab." Cancers 14.22 (2022): 5659.
- 3. Trontzas, Ioannis P., and Konstantinos N. Syrigos. "Immune biomarkers for checkpoint blockade in solid tumors: transitioning from tissue to peripheral blood monitoring and future integrated strategies." Cancers 17.16 (2025): 2639.
- 4. Ucgul, Enes, et al. "Factors influencing immunotherapy outcomes in cancer: sarcopenia and systemic inflammation." Cancer Control 31 (2024): 10732748241302248.
- 5. Fujiwara, Ryo, et al. "Modified Glasgow prognostic score as a predictor of prognosis in metastatic renal cell carcinoma treated with nivolumab." Clinical Genitourinary Cancer 19.2 (2021): e78-e83.
- 6. Tong, Tongyu, et al. "A meta-analysis of Glasgow prognostic score and modified Glasgow prognostic score as biomarkers for predicting survival outcome in renal cell carcinoma." Frontiers in Oncology 10 (2020): 1541.
- 7. Atkins, Michael B. "Overview of the treatment of renal cell carcinoma." Literature review current through: Oct (2012).
- 8. Nozoe, Tadahiro, et al. "Glasgow Prognostic Score (GPS) can be a useful indicator to determine prognosis of patients with colorectal carcinoma." International surgery 99.5 (2014): 512-517.
- 9. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–63.
- 10. Gupta D, et al. The prognostic value of serum albumin in cancer: a meta-analysis. J Cancer. 2009;3(1):18–31.